Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus

Phase 1 Completed 64 enrolled Fujian Shengdi Pharmaceutical Co., Ltd.

RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to assess the safety and tolerability of multiple subcutaneous injections of HRS9531 in patients with type 2 diabetes mellitus who have suboptimal glycaemic control after conventional lifestyle or metformin intervention.

Timeline

Start: 2022-10-12
Primary completion: 2023-05-24
Completion: 2023-05-24

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Dulaglutide	Peptide	1.5 mg	Subcutaneous
Subject	HRS9531	Unknown	—	Subcutaneous

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus

Summary

Timeline

Drugs

Indications